Daiichi Sankyo submits edoxaban to European regulators

• Daiichi Sankyo (OTCPK:DSKYF +1.2%) submits a MAA for edoxaban.
  
• The company wants the direct factor Xa-inhibitor approved for stroke and SEE prevention in NVAF patients, for the treatment of DVT or PE, and for the prevention of VTE.
• For more on edoxaban, see here.